PL327919A1 - Antagonists of vitronectin receptors - Google Patents
Antagonists of vitronectin receptorsInfo
- Publication number
- PL327919A1 PL327919A1 PL96327919A PL32791996A PL327919A1 PL 327919 A1 PL327919 A1 PL 327919A1 PL 96327919 A PL96327919 A PL 96327919A PL 32791996 A PL32791996 A PL 32791996A PL 327919 A1 PL327919 A1 PL 327919A1
- Authority
- PL
- Poland
- Prior art keywords
- antagonists
- vitronectin receptors
- vitronectin
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US953295P | 1995-12-29 | 1995-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL327919A1 true PL327919A1 (en) | 1999-01-04 |
Family
ID=21738237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL96327919A PL327919A1 (en) | 1995-12-29 | 1996-12-20 | Antagonists of vitronectin receptors |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0895475A4 (en) |
| JP (1) | JP2000502708A (en) |
| KR (1) | KR19990076876A (en) |
| CN (1) | CN1209060A (en) |
| AU (1) | AU1353897A (en) |
| BR (1) | BR9612378A (en) |
| CA (1) | CA2241724A1 (en) |
| CZ (1) | CZ203798A3 (en) |
| HU (1) | HUP9901116A2 (en) |
| IL (1) | IL125034A0 (en) |
| MX (1) | MX9805253A (en) |
| NO (1) | NO983002L (en) |
| PL (1) | PL327919A1 (en) |
| TR (1) | TR199801255T2 (en) |
| WO (1) | WO1997024122A1 (en) |
| ZA (1) | ZA9610855B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0777657A1 (en) * | 1994-08-22 | 1997-06-11 | Smithkline Beecham Corporation | Bicyclic compounds |
| EP0880511A4 (en) * | 1996-01-16 | 1999-06-16 | Merck & Co Inc | Integrin receptor antagonists |
| JP2000508319A (en) * | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3 antagonist |
| US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| DE19653647A1 (en) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
| DE19653645A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
| WO1999005107A1 (en) * | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| EP1047425A4 (en) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | Integrin receptor antagonists |
| EA200000921A1 (en) * | 1998-03-10 | 2001-04-23 | Смитклайн Бичам Корпорейшн | ANTAGONISTS OF THE VITRONECTIN RECEPTOR |
| WO1999050262A1 (en) * | 1998-04-01 | 1999-10-07 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
| GB9812088D0 (en) * | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| SE9803518D0 (en) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
| AU747503B2 (en) | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| CA2378860A1 (en) | 1999-07-21 | 2001-02-01 | American Home Products Corporation | Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| DE10028575A1 (en) | 2000-06-14 | 2002-03-14 | Basf Ag | integrin |
| FR2800067B1 (en) * | 1999-10-21 | 2004-12-17 | Rhodia Chimie Sa | INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES |
| FR2820743B1 (en) * | 2001-02-09 | 2005-02-25 | Pf Medicament | SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES |
| US20040136949A1 (en) | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
| CA2541989C (en) * | 2003-10-24 | 2013-10-01 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2006041046A1 (en) * | 2004-10-13 | 2006-04-20 | Sankyo Company, Limited | Pyridine derivative |
| KR20080004554A (en) | 2005-04-20 | 2008-01-09 | 얀센 파마슈티카 엔.브이. | Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls |
| EP2338518A1 (en) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| TW200811164A (en) * | 2006-05-12 | 2008-03-01 | Jerini Ag | New heterocyclic compounds for the inhibition of integrins and use thereof |
| MX2009007597A (en) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer. |
| US9345739B2 (en) | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| JP2012527474A (en) | 2009-05-22 | 2012-11-08 | エクセリクシス， インク． | Benzoxazepine-based PI3K / MT0R inhibitors for proliferative diseases |
| BRPI1011206A2 (en) | 2009-05-25 | 2016-03-15 | Merck Patent Gmbh | continuous administration of integrin ligands to treat cancer |
| EP2513037B1 (en) * | 2009-12-17 | 2014-04-02 | Basf Se | Method for producing higher ethanolamines |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| KR20160147007A (en) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | Carbonitrile derivatives as selective androgen receptor modulators |
| PE20190971A1 (en) | 2016-06-13 | 2019-07-09 | Glaxosmithkline Ip Dev Ltd | CHEMICAL COMPOUNDS |
| CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| WO2018160522A1 (en) | 2017-02-28 | 2018-09-07 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202035400A (en) | 2018-08-29 | 2020-10-01 | 美商莫菲克醫療股份有限公司 | Inhibiting αvβ6 integrin |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
| PT100631B (en) * | 1991-06-28 | 1999-06-30 | Smithkline Beecham Corp | BICYCLE FIBRINOGENIC ANTAGONISTS, ITS USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| SG63579A1 (en) * | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
| EP0762882A4 (en) * | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| CN1209063A (en) * | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | Vitronection receptor antagonists |
| ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 KR KR1019980705003A patent/KR19990076876A/en not_active Application Discontinuation
- 1996-12-20 BR BR9612378A patent/BR9612378A/en unknown
- 1996-12-20 PL PL96327919A patent/PL327919A1/en unknown
- 1996-12-20 WO PCT/US1996/020744 patent/WO1997024122A1/en not_active Application Discontinuation
- 1996-12-20 HU HU9901116A patent/HUP9901116A2/en unknown
- 1996-12-20 TR TR1998/01255T patent/TR199801255T2/en unknown
- 1996-12-20 IL IL12503496A patent/IL125034A0/en unknown
- 1996-12-20 CN CN96180099A patent/CN1209060A/en active Pending
- 1996-12-20 AU AU13538/97A patent/AU1353897A/en not_active Abandoned
- 1996-12-20 CA CA002241724A patent/CA2241724A1/en not_active Abandoned
- 1996-12-20 JP JP9524556A patent/JP2000502708A/en active Pending
- 1996-12-20 EP EP96945085A patent/EP0895475A4/en not_active Withdrawn
- 1996-12-20 CZ CZ982037A patent/CZ203798A3/en unknown
- 1996-12-23 ZA ZA9610855A patent/ZA9610855B/en unknown
-
1998
- 1998-06-26 NO NO983002A patent/NO983002L/en not_active Application Discontinuation
- 1998-06-26 MX MX9805253A patent/MX9805253A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL125034A0 (en) | 1999-01-26 |
| JP2000502708A (en) | 2000-03-07 |
| EP0895475A4 (en) | 2000-08-23 |
| NO983002L (en) | 1998-08-26 |
| KR19990076876A (en) | 1999-10-25 |
| EP0895475A1 (en) | 1999-02-10 |
| HUP9901116A2 (en) | 2000-03-28 |
| TR199801255T2 (en) | 1998-10-21 |
| BR9612378A (en) | 1999-07-13 |
| MX9805253A (en) | 1998-10-31 |
| ZA9610855B (en) | 1997-11-24 |
| CZ203798A3 (en) | 1998-12-16 |
| WO1997024122A1 (en) | 1997-07-10 |
| CA2241724A1 (en) | 1997-07-10 |
| NO983002D0 (en) | 1998-06-26 |
| CN1209060A (en) | 1999-02-24 |
| AU1353897A (en) | 1997-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL327919A1 (en) | Antagonists of vitronectin receptors | |
| PL318199A1 (en) | Antagonists of vitronectin receptors | |
| PL327626A1 (en) | Antagonists of vitronectin receptor | |
| PL327694A1 (en) | Antagonists of vitronectin receptor | |
| PL328562A1 (en) | Antagonists of il-8 receptors | |
| PL334499A1 (en) | Antagonists of vitronectin receptors | |
| PL320010A1 (en) | Indolyllic antagonists of neuropeptide y receptors | |
| ZA955391B (en) | Vitronectin receptor antagonists | |
| PL330850A1 (en) | Antagonists of il-8 receptors | |
| PL330849A1 (en) | Antagonists of il-8 receptors | |
| CY2576B1 (en) | Vitronectin receptor antagonists | |
| PL341114A1 (en) | Antagonists of thrombosin receptors | |
| PL339381A1 (en) | Antagonists of vitronectin receptor | |
| PL310386A1 (en) | Antagonists of factor i receptors | |
| ZA952461B (en) | Antagonists of endothelin receptors | |
| PL320638A1 (en) | Antagonists of endothein receptors | |
| IL118299A0 (en) | Pharmacological use of AII-receptor antagonists | |
| ZA968093B (en) | Additional antagonists of endothelin receptors | |
| GB9519885D0 (en) | Antagonists of a-1 adrenergic receptors | |
| GB9506282D0 (en) | Antagonists of A-1C adrenergic receptors | |
| GB9524704D0 (en) | Antagonists of a-1c adrenergic receptors | |
| ZA959855B (en) | Antagonists of alpha 1c adrenergic receptors | |
| SI0957917T1 (en) | Vitronectin receptor antagonists | |
| ZA988562B (en) | Vitronectin receptor antagonists |